Bimekizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL17A,IL17F,IL17AF |
| Clinical data | |
| Trade names | Bimzelx |
| Other names | UCB4940, bimekizumab-bkzx |
| License data | |
| Pregnancy category | |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6552H10132N1750O2029S42 |
| Molar mass | 147229.87g·mol−1 |
Bimekizumab,sold under the brand nameBimzelx,is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AFmonoclonal antibody[6][7]that is used to treatplaque psoriasis,psoriatic arthritis,axial spondyloarthritis,andankylosing spondylitis.[6]
The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[6]Injection site reactionswere also common, reported in 3% of subjects.[8]
Bimekizumab was approved for medical use in the European Union in August 2021,[6][9][10]and in the United States in October 2023.[11][12]
Medical uses[edit]
In the EU, bimekizumab isindicatedfor the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.[6]
History[edit]
Bimekizumab is being developed by Belgian pharmaceutical companyUCB.[citation needed]
Society and culture[edit]
Names[edit]
Bimekizumab is theinternational nonproprietary name(INN).[13]
Research[edit]
Phase III trials have demonstrated that bimekizumab is superior to not onlyadalimumab[14]but alsosecukinumab[15]andustekinumab[16]for the treatment of plaque psoriasis.
References[edit]
- ^ab"Bimzelx APMDS".Therapeutic Goods Administration (TGA).7 April 2022.Archivedfrom the original on 24 April 2022.Retrieved24 April2022.
- ^"Updates to the Prescribing Medicines in Pregnancy database".Therapeutic Goods Administration (TGA).21 December 2022.Archivedfrom the original on 3 April 2022.Retrieved2 January2023.
- ^"Bimzelx Product information".Health Canada.25 April 2012.Archivedfrom the original on 29 June 2022.Retrieved29 June2022.
- ^"Regulatory Decision Summary for Bimzelx".Drug and Health Products Portal.23 February 2024.Retrieved1 April2024.
- ^"Bimzelx- bimekizumab injection, solution".DailyMed.20 October 2023.Retrieved10 November2023.
- ^abcdef"Bimzelx EPAR".European Medicines Agency(EMA).23 June 2021.Archivedfrom the original on 25 August 2021.Retrieved24 August2021.Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^Lim SY, Oon HH (13 May 2019)."Systematic review of immunomodulatory therapies for hidradenitis suppurativa".Biologics: Targets & Therapy.13:53–78.doi:10.2147/BTT.S199862.PMC6526329.PMID31190730.
- ^FDA Professional Drug Information
- ^"Bimzelx Product information".Union Register of medicinal products.Archivedfrom the original on 4 March 2023.Retrieved3 March2023.
- ^"UCB Announces European Commission Approval of Bimzelx (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis".UCB(Press release). 24 August 2021.Archivedfrom the original on 25 August 2021.Retrieved24 August2021.
- ^Frellick M (18 October 2023)."FDA Approves Bimekizumab for Plaque Psoriasis in Adults".Medscape.Archivedfrom the original on 28 October 2023.Retrieved28 October2023.
- ^"Bimzelx Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis".UCB(Press release). 18 October 2023.Archivedfrom the original on 28 October 2023.Retrieved28 October2023.
- ^World Health Organization(2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72".WHO Drug Information.28(3).hdl:10665/331112.
- ^Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, et al. (July 2021)."Bimekizumab versus Adalimumab in Plaque Psoriasis".The New England Journal of Medicine.385(2): 130–141.doi:10.1056/NEJMoa2102388.PMID33891379.S2CID233372177.
- ^Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. (July 2021)."Bimekizumab versus Secukinumab in Plaque Psoriasis".The New England Journal of Medicine.385(2): 142–152.doi:10.1056/NEJMoa2102383.PMID33891380.S2CID233370455.
- ^Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, et al. (February 2021). "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial".Lancet.397(10273): 487–498.doi:10.1016/S0140-6736(21)00125-2.PMID33549193.S2CID231809826.
